Acetazolamide is a carbonic anhydrase
inhibitor used to treat chronic simple (open-angle) glaucoma, secondary
glaucoma, and acute angle-closure glaucoma, epilepsy, edoema from congestive
heart failure, drug-induced edoema, and acute mountain sickness in climbers.
Acetazolamide aids altitude adaptation by increasing renal bicarbonate
production, inducing metabolic acidosis, and stimulating breathing.
Furthermore, acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily is more
effective than placebo in preventing acute mountain sickness, according to the
BMJ Journal, September 2012. Furthermore, the lowest effective dose for
preventing acute mountain sickness is acetazolamide 250 mg daily.
Extended Application of Acetazolamide in
Various Treatment Modalities is expected to Drive Market Growth during the
Forecast Period
Acetazolamide is useful to prevent
high altitude illness in most people, which is characterised by headache,
nausea, vomiting, and exhaustion (often referred to as acute mountain
sickness), however it can harm the brain or lungs in certain people. When
compared to a placebo, acetazolamide is an effective and superior treatment for
the prevention of acute high altitude illness (HAI) in dosages of 250 to 750
mg/day, according to a study published in the Cochrane Journal in June 2017.
Acetazolamide is a medication that prevents acute mountain sickness and has
less adverse effects than dexamethasone. In the United Kingdom, according to
the BMJ journal, prescribing acetazolamide
market for travel is an optional service that is not included in the
general practitioner's contract.
Acetazolamide, an altitude sickness
medicine, has been found to help overcome resistance to the chemotherapy treatment
temozolomide, according to researchers at the University of Chicago, who
published their findings in the journal Science Translational Medicine in July
2018. (TMZ). Although TMZ is commonly used in the treatment of gliomas, some
people do not respond to it. Researchers discovered an increase in survival
rates in pre-clinical glioma models with the addition of acetazolamide.
Acetazolamide, when combined with TMZ, increased survival in animal models by
30 to 40%, according to this study. The usage of acetazolamide
market as an alternate treatment approach for lowering chemotherapy
resistance in the treatment of gliomas should provide attractive growth
potential for the medicine in the near future.
Increasing Prevalence of Glaucoma among Global
Population is expected to Aid in Market Growth
The rising global prevalence of
glaucoma and associated risk factors such as high myopia, diabetes, eye surgery
or injury, high blood pressure, increased use of corticosteroids, and a family
history of glaucoma are expected to provide favourable future growth
opportunities for acetazolamide drug manufacturers. Acetazolamide, when taken
as a daily sustained release capsule, has a significant pressure-lowering
impact that lasts at least 23 hours. Acetazolamide treatment lowers ocular
pressure, which helps to prevent damage to the eyes. Acetazolamide lowers
ocular pressure by inhibiting the function of an enzyme called carbonic
anhydrase, which reduces the quantity of fluid secreted in the front region of
the eye.
Comments
Post a Comment